Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers. 2021; 13: 779
- Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.Molecules. 2020; 25: 1743
- The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.Am Soc Clin Oncol Educ Book. 2019; 39: 321-330
- Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?.J Clin Oncol. 2022; 40: 3011-3014
- Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.Hum Pathol. 2000; 31: 578-583
- Treatment and prevention of bone complications from prostate cancer.Bone. 2011; 48: 88-95
- Radium-223 mechanism of action: implications for use in treatment combinations.Nat Rev Urol. 2019; 16: 745-756
- Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med. 2013; 369: 213-223
- [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.Lancet. 2021; 397: 797-804
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med. 2021; 385: 1091-1103
- Actinium-225 in targeted alpha-particle therapeutic applications.Curr Radiopharm. 2011; 4: 306-320
- 225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.J Nucl Med. 2016; 57: 1941-1944
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.Eur Urol. 2021; 79: 343-350
- Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).J Clin Oncol. 2021; 39
- 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT.J Clin Oncol. 2022; 40
- Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer.Cancer. 2019; 125: 2561-2569
- PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).J Clin Oncol. 2022; 40
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med. 2020; 382: 2091-2102
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med. 2020; 383: 2345-2357
- Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.Oncotarget. 2018; 9: 24693-24706
- Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.Sci Rep. 2020; 10: 10196
- Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo.Clin Cancer Res. 2018; 24: 3994-4005
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.J Clin Oncol. 2016; 34: 3005-3013
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).Lancet Oncol. 2022; 23: 899-909
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004; 351: 1502-1512
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet. 2010; 376: 1147-1154
- Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.Eur J Cancer. 2019; 114: 107-116
- Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177)Lu-J591) for metastatic castration-resistant prostate cancer.Urol Oncol. 2020; 38: 848 e9-e16
- The Outcome and Safety of Re-challenge Lutetium-177 PSMA ((177)Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.Nucl Med Mol Imaging. 2021; 55: 136-140
- Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond.Am Soc Clin Oncol Educ Book. 2022; 42: 1-17
- Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.Cancer Imag. 2020; 20: 23
- Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naive Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study.J Nucl Med. 2022; 63: 1531-1536
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.Eur Urol. 2019; 76: 469-478
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.J Nucl Med. 2018; 59: 469-478
- The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis.J Nucl Med. 2022; 63: 1644-1650
- Tumor Sink Effect in (68)Ga-PSMA-11 PET: Myth or Reality?.J Nucl Med. 2022; 63: 226-232
- A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.Cancers. 2022; 14: 4276
- Dosimetry of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.J Nucl Med. 2019; 60: 517-523
Article info
Publication history
Published online: February 20, 2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
